New immunotherapy treatment for liver cancer returning after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old and able to attend all study visits and follow instructions
- You must have had liver cancer surgery before and now have confirmed cancer recurrence between 3 months and 2 years after that surgery
- Your liver function must be healthy enough to safely remove the recurrent tumor (Child-Pugh Class A)
- You need adequate blood counts, kidney function, and liver function based on recent blood tests
- You cannot have received prior immunotherapy (PD-1/PD-L1 drugs) or be pregnant/breastfeeding
- You must have a tumor that can be measured and has not received local treatment (like radiation or ablation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests whether giving an immunotherapy drug (anti-PD-1) after surgery can help prevent liver cancer from coming back. It is for people who have had their liver tumor completely removed and have good enough liver function.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.